Copyright © 2002 by the European Society of Cardiology.
Editorials
Thrombin inhibitors in acute coronary artery disease
Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York, U.S.A.
References
- Braunwald E, Antman EM, Beasley JW. ACC/AHA Guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. J Am Coll Cardiol. 2000;36:9701062
[Free Full Text] - Bertrand ME, Simoons ML, Fox KAA. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Eur Heart J. 2000;21:14061432
[Free Full Text] - Antman EM. The search for replacements for unfractionated heparin. Circulation. 2001;103:2310
[Free Full Text] - Meyer BJ, Badimon JJ, Chesebro JH. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin. Circulation. 1998;97:681685
[Abstract/Free Full Text] - Andreotti F. The TIMI 9B and GUSTO-IIb Trials and the Thrombin Hypothesis. J Thromb Thrombolysis. 1997;4:311313[CrossRef][Medline]
- Kottke-Marchant K, Bahit MC, Granger CB. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy. Eur Heart J. 2002;23:12021212
[Abstract/Free Full Text] - Cannon CP, Weintraub WS, Demopoulos LA. the TACTICSThrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:18791887
[Abstract/Free Full Text] - Vorchheimer DA, Badimon JJB, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA. 1999;281:14071414
[Abstract/Free Full Text] - N Engl J Med. 2001;345:494502
[Abstract/Free Full Text] - Reverter JC, Beguin S, Kessels H, Jumar R, Coller BS. Inhibition of platelet-mediated, tissue factor induced thrombin generation by the mouse/chimeric 7E3 antiboty: potential implications for the effects of abciximab treatment on acute thrombosis and clinical retsenosis. J Clin Invest. 1996;98:863874[Web of Science][Medline]
- Mehta SR, Eikelboom JW, Rupprecht H-J. Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention. Eur Heart J. 2002;23:117123
[Abstract/Free Full Text] - White HD. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001;358:18551863[CrossRef][Web of Science][Medline]
- Corti R, Fuster V, Badimon JJ. Strategy for ensuring a better future for the vessel wall. Eur Heart J. 2002;4:A31A41
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||